EP0042, a Dual FLT3 and Aurora Kinase Inhibitor
Suzanne Wood
FDA clearance of IND application for EP0031
FDA clearance of IND application for EP0031 Ellipses announces FDA clearance of IND application for EP0031 for patients with advanced RET-altered malignancies A phase 1/2 trial to initiate across a range of patient populations with RET-altered cancers Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments [...]Exclusive licensing agreement
Exclusive licensing agreement Ellipses Pharma and SunRock Biopharma enter into a licensing agreement for a first-in-class bifunctional HER3:TRAIL fusion protein Ellipses Pharma granted exclusive global rights to develop and commercialise SRB22, in solid tumours LONDON and SANTIAGO DE COMPOSTELA, Spain, May 25th, 2022: SunRock Biopharma S.L. (“SunRock”), a biopharmaceutical company that is developing a portfolio [...]Our new Global Head of Drug Development and Chief Medical Officer
Our new Global Head of Drug Development and Chief Medical Officer Ellipses Pharma Announces Appointment of Professor Hendrik-Tobias Arkenau as Global Head of Drug Development and Chief Medical Officer Highly Accomplished Oncologist with Proven Track Record in Leading Innovative Drug Development Ellipses Pharma a global drug development company focused on accelerating the development of new [...]Meet us digitally at the Bio-Europe Spring conference
Meet us digitally at the Bio-Europe Spring conference For more information, send us a mail at enquiries@ellipses.lifeEllipses Announces Growth in Oncology Portfolio
Ellipses Announces Growth in Oncology Portfolio ELLIPSES ANNOUNCES GROWTH IN ONCOLOGY PORTFOLIO LONDON, September 16, 2021: Ellipses Pharma, the UK-based global drug development company, has today announced a significant increase in its portfolio of potential treatments for a range of cancers. Ellipses has now acquired and is developing seven high-quality drugs of which two are [...]Kelun and Ellipses Announce a Licensing Agreement for A400
Kelun and Ellipses Announce a Licensing Agreement for A400 Kelun-Biotech and Ellipses Pharma Announce a Licensing Agreement for A400 Sichuan Kelun-Biotech Pharmaceutical Co., Ltd. and UK company Ellipses Pharma Ltd. Announce a Licensing Agreement for Innovative Small Molecule Cancer Therapeutics Sichuan Kelun-Biotech Pharmaceutical Co., Ltd. (hereinafter referred to as “Kelun-Biotech”), a subsidiary of Sichuan Kelun [...]Resistance-Busting ICR Drug Enters Clinical Trial
Resistance-Busting ICR Drug Enters Clinical Trial Resistance-busting ICR drug enters clinical trial A drug discovered at The Institute of Cancer Research, London, that could counteract drug resistance in patients with cancers including acute myeloid leukaemia has entered a phase I clinical trial at The Royal Marsden NHS Foundation Trust. The drug, now called EP0042, is [...]